During the corresponding time, Neuropace Inc saw a revenue deteriorated by -1.32 % year on year, sequentially revenue grew by 3.53 %. While revenue at the Neuropace Inc 's corporate clients
Neuropace Inc's Comment on Sales, Marketing and Customers
The company provides treatment for patients with drug-resistant epilepsy, primarily focusing on adults with drug-resistant focal epilepsy at Level 4 Comprehensive Epilepsy Centers (CECs) and within the community. It targets approximately 24,000 adult patients annually in the U.S. at these centers. The company plans to expand its indications to include patients with generalized epilepsy, estimated at 20,000 individuals, and patients under 18 years old, approximately 6,000 individuals. It is pursuing FDA approval to include drug-resistant idiopathic generalized epilepsy in its indications. The company collaborates with third parties, including Rapport Therapeutics, Inc., utilizing the RNS System's biomarker monitoring and data analysis capabilities to support the development of additional epilepsy therapies. It also intends to expand into international markets.
Advancements in Neuromodulation: NeuroPace s RNS System Demonstrates Promising Outcomes in Focal Epilepsy : The advent of neuromodulation technologies has ushered in innovative therapeutic modalities for managing drug-resistant neurological disorders such as focal epilepsy. NeuroPace, a leading entity in neuromodulation, has recently submitted compelling three-year data to the FDA from their RNS System Post-Approval Study (PAS), which stands as the largest prospective study of its kind, aimed at evaluating the efficacy and safety of the RNS System in patients with drug-resistant focal epilepsy. Concurrently, NeuroPace Inc. has reported a substantial 56.59% annual increase in revenue, alongside a quarterly...
NeuroPace Inc., a leading pioneer in neurostimulation technology, has recently announced the successful completion of patient enrollment in its groundbreaking NAUTILUS Pivotal Study. NAUTILUS is the first-ever pivotal clinical trial aimed at evaluating the effectiveness of neuromodulation therapy in treating drug refractory idiopathic generalized epilepsy. This significant milestone not only holds promise for millions of epilepsy patients worldwide but also showcases NeuroPace s commitment to advancing medical innovation. Alongside this achievement, the company has reported remarkable revenue growth, further solidifying its position as a trailblazer in the field.Unleashing the Potential of Neuromodulation Th...
Neuropace Inc’s Comment on Sales, Marketing and Customers
The company provides treatment for patients with drug-resistant epilepsy, primarily focusing on adults with drug-resistant focal epilepsy at Level 4 Comprehensive Epilepsy Centers (CECs) and within the community. It targets approximately 24,000 adult patients annually in the U.S. at these centers. The company plans to expand its indications to include patients with generalized epilepsy, estimated at 20,000 individuals, and patients under 18 years old, approximately 6,000 individuals. It is pursuing FDA approval to include drug-resistant idiopathic generalized epilepsy in its indications. The company collaborates with third parties, including Rapport Therapeutics, Inc., utilizing the RNS System's biomarker monitoring and data analysis capabilities to support the development of additional epilepsy therapies. It also intends to expand into international markets.
Sources:
Neuropace Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Neuropace Inc’s corporate clients.
For your research, we’ve provided 9 tables on Neuropace Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
4.82 %